Physician profile
Darin Wilson
NPI 1497755706
$1,346.48
in general payments reported to CMS, 2019-2025
18 companies · $210 in 2025
The $210 reported for 2025 was more than what 77% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $66.92 · 2021: $217 · 2022: $218 · 2023: $228 · 2024: $259 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $414.86 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.77 | 2020-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $117.15 | 2019-2025 | Farxiga, Lokelma |
| Pfizer INC. | $110.57 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $64.93 | 2019-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.22 | 2019-2023 | Xifaxan |
| Melinta Therapeutics, LLC | $61.26 | 2024-2025 | Orbactiv |
| La Jolla Pharmaceutical Company | $52.24 | 2023-2024 | Xerava |
| Alexion Pharmaceuticals, INC. | $51.41 | 2024 | Ultomiris, Soliris |
| Smith+Nephew, INC. | $50.89 | 2025 | Collagenase Santyl |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.51 | 2021-2025 | Lifevest |
| Abbott Laboratories | $41.96 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Gilead Sciences, INC. | $39.40 | 2023-2024 | |
| Genzyme Corporation | $27.55 | 2024 | |
| Stryker Corporation | $26.60 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.85 | 2024 | Repatha |
| Ucb, INC. | $22.47 | 2019 | |
| Bioxcel Therapeutics, INC. | $12.84 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.